Verrica Pharmaceuticals SEC Filings

Verrica Pharmaceuticals Inc. director Diem Nguyen received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.04 per share and expire on June 4, 2036.

These options were granted as compensation and vest in 12 equal monthly installments beginning on July 5, 2026. They will in any event be fully vested on the date of the next annual meeting of stockholders, subject to Nguyen’s continued service as a director through each vesting date.

Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.0400 per share and represent equity-based compensation rather than an open-market purchase.

These options vest in 12 equal monthly installments beginning on July 5, 2026 and will in any event be fully vested by the date of the next annual meeting of stockholders, subject to his continued service as a director through each vesting date. Following this grant, he holds 16,000 derivative securities directly.

Verrica Pharmaceuticals Inc. CMO Noah L. Rosenberg received a grant of employee stock options for 233,840 shares of Common Stock. The options carry an exercise price of $8.21 per share and expire on December 23, 2035.

The grant was approved by a board committee on December 23, 2025, subject to shareholder approval of an amendment to Verrica's 2018 Equity Incentive Plan, which shareholders later approved on June 5, 2026. All 233,840 options are held directly and are compensation-related.

Vesting is performance-based: 50% of the options vest when the closing sales price on The Nasdaq Capital Market reaches at least $15.00 per share, and the remaining 50% vest when the price reaches at least $25.00 per share, subject to Rosenberg's continuous service through each vesting date.

Verrica Pharmaceuticals Inc. reported that Chief Operating Officer David Zawitz received a grant of employee stock options for 171,340 shares of common stock. The options have an exercise price of $8.21 per share and expire on December 23, 2035.

The grant was approved by a board committee on December 23, 2025, subject to shareholder approval of an amendment to the 2018 Equity Incentive Plan, which shareholders granted on June 5, 2026. Half of the options vest only if the share price reaches $15.00, and the other half vest if the share price reaches $25.00, in each case subject to Zawitz’s continuous service.

Verrica Pharmaceuticals CEO and President Jayson Rieger was granted an employee stock option covering 512,269 shares of common stock at an exercise price of $8.21 per share. The option expires on December 23, 2035 and vests in two tranches tied to share-price hurdles.

Half of the option vests if Verrica’s Nasdaq closing price reaches at least $15.00 per share, and the other half vests if it reaches at least $25.00 per share, in each case subject to his continued service. The grant was originally approved in December 2025 and became effective after shareholders approved an amendment to the 2018 Equity Incentive Plan on June 5, 2026.

Verrica Pharmaceuticals director Gavin Corcoran received a grant of stock options covering 16,000 shares of common stock at an exercise price of $6.04 per share. These options vest in 12 equal monthly installments beginning on July 5, 2026, and will be fully vested by the next annual stockholder meeting, subject to his continued service. Following this compensation award, Corcoran holds 16,000 stock options directly.

Verrica Pharmaceuticals reported results of its 2026 annual stockholder meeting. Stockholders approved the Amended and Restated 2018 Equity Incentive Plan, which became effective immediately after the vote. They also re-elected Paul B. Manning and Lawrence Eichenfield as directors to serve until the 2029 annual meeting.

Advisory compensation for named executive officers was approved, and KPMG LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026. Approximately 81.89% of the 17,178,786 shares outstanding as of the record date were present or represented by proxy.

Verrica Pharmaceuticals reported first-quarter 2026 revenue of $5.0 million, up from $3.4 million a year earlier, driven mainly by higher YCANTH product revenue of $4.3 million. License and collaboration revenue contributed $0.7 million, largely from its Torii Pharmaceuticals agreement.

The company recorded a net loss of $9.7 million, similar to the prior-year period, and an accumulated deficit of $334.6 million as of March 31, 2026. Cash totaled $20.6 million, with operating activities using $9.2 million of cash in the quarter.

Management states there is substantial doubt about Verrica’s ability to continue as a going concern within one year without additional financing. The company plans to seek new capital through equity or debt financings and partnerships while advancing YCANTH for common warts and its oncology candidate VP-315.

Verrica Pharmaceuticals reported first quarter 2026 results showing strong growth in its lead product YCANTH while remaining loss-making overall. Total revenue reached $5.0 million, including $4.3 million in U.S. YCANTH net product revenue, with management highlighting double-digit growth versus both the prior quarter and prior year.

Dispensed YCANTH applicator units rose to 15,302 in Q1 2026 and have now exceeded 100,000 since launch, reflecting rising demand in molluscum contagiosum. The company also noted the first ex‑U.S. commercial launch of YCANTH in Japan through partner Torii Pharmaceutical.

Despite revenue growth, Verrica posted a GAAP net loss of $9.7 million, or $(0.45) per share, compared with a $9.7 million loss, or $(1.03) per share, a year earlier. Cash declined to $20.6 million as of March 31, 2026. Verrica continues to invest in its pipeline, advancing VP‑315 in basal cell carcinoma and running a global Phase 3 program of YCANTH in common warts, where the first trial has surpassed 50% of targeted enrollment.